Personalis Publishes Study Highlighting NeXT Personal's Role in Immunotherapy Monitoring

Personalis announced the publication of a new study in npj Precision Oncology highlighting the power of its ultrasensitive molecular residual disease, or MRD, assay, NeXT Personal, in monitoring immunotherapy response across a broad range of advanced cancers. The study, titled "Ultrasensitive ctDNA monitoring reveals early predictors of immunotherapy response in advanced cancer," was led by oncology researchers at UC San Diego Moores Cancer Center. The findings reinforce the NeXT Personal test's ability to detect circulating tumor DNA (ctDNA) at ultrasensitive levels, providing a window for earlier clinical intervention that other approaches may miss. The NeXT Personal test achieves ultrasensitive detection of small traces of ctDNA from a patient's blood sample using a personalized approach that tracks up to ~1,800 tumor-specific variants unique to each patient's tumor. While immunotherapy has transformed cancer care, only ~10-40% of patients achieve durable benefit, making it critical to monitor how patients are responding to therapy. This interim analysis of the ongoing study includes 39 patients with advanced solid tumors treated with immune checkpoint inhibitors alone or in combination with other therapies. Key findings include: Early identification of therapy response; Lead time over imaging; Criticality of the ultrasensitive range in advanced tumors; Strong correlation with outcomes.